Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Colorectal Neoplasms 86Ovarian Neoplasms 33Breast Neoplasms 29Carcinoma, Non-Small-Cell Lung 28Colonic Neoplasms 23Rectal Neoplasms 21Fallopian Tube Neoplasms 17Neoplasms 16Neoplasm Metastasis 13Carcinoma, Hepatocellular 13Glioblastoma 11Lung Neoplasms 10Brain Neoplasms 8Carcinoma, Renal Cell 7Uterine Cervical Neoplasms 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Intestinal Neoplasms 5Gastrointestinal Neoplasms 5Digestive System Neoplasms 5Brenner Tumor 5Recurrence 4Peritoneal Neoplasms 4Glioma 4Carcinoma, Ovarian Epithelial 4Adenocarcinoma of Lung 4Rectal Diseases 3Non-Squamous Non-Small Cell Lung Cancer 3Liver Neoplasms 3Intestinal Diseases 3Gastrointestinal Diseases 3

Interventions

Pemetrexed 3Carboplatin 3pembrolizumab 2patritumab 1osimertinib 1napabucasin 1camrelizumab 1aflutinib 1Vinorelbine 1TNFSF10 protein, human 1Paclitaxel 1Injections 1Gemcitabine 1Erlotinib Hydrochloride 1Docetaxel 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Bronchial Neoplasms × Bevacizumab × Clear all
NCT05104281 2023-03-29

Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer

Qingdao Central Hospital

Phase 3 Unknown
60 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡